文献速递前列腺癌

18F-FDG PET/CT预后价值可延伸至预测mCRPC系统治疗缓解持续时间

The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-05-19

该回顾性研究纳入114例mCRPC患者,评估FDG-PET/CT代谢参数与总生存及治疗缓解时间的关系。多因素分析显示仅MTV可独立预测OS(p<0.0001),亚组中PSA和TLG可独立预测治疗缓解持续时间(p<0.05)。较低TLG与ARTA更高成功率相关,但对化疗疗效无影响。

要点

  • MTV可独立预测mCRPC患者总生存(p<0.0001)。
  • TLG和PSA可独立预测系统治疗缓解持续时间(p<0.05)。
  • 较低TLG与ARTA治疗更高成功率相关,对化疗疗效无影响。

核心结论

  • FDG-PET/CT的预后价值可延伸至预测mCRPC患者系统治疗缓解持续时间,可能有助于指导系统治疗选择。

研究设计与样本

  • 回顾性纳入2005至2020年四家意大利中心的114例mCRPC患者,中位随访15个月。
  • 计算最热病灶SUVmax、总代谢肿瘤体积(MTV)和总病灶糖酵解(TLG)。
  • 在化疗(多西他赛或卡巴他赛,24例)或ARTA(阿比特龙或恩扎卢胺,20例)前6个月内行FDG-PET/CT的亚组中评估治疗缓解预测。

主要发现

  • 单因素分析中PSA、碱性磷酸酶(ALP)、MTV和TLG与OS相关。
  • 多因素Cox回归分析中仅MTV可独立预测OS(p<0.0001)。
  • 在系统治疗前FDG-PET/CT亚组中,PSA和TLG可独立预测治疗缓解持续时间(p<0.05)。
  • 较低TLG与ARTA更高成功率相关,但对化疗疗效无影响。

关键数值与推荐

  • MTV独立预测OS的p<0.0001。
  • PSA和TLG独立预测治疗缓解持续时间的p<0.05。

临床怎么用

  • FDG-PET/CT代谢参数(尤其MTV和TLG)可用于mCRPC预后评估和治疗缓解预测。
  • 较低TLG可能提示ARTA治疗成功率更高,但对化疗选择无指导意义。

局限性

  • 回顾性研究设计。
  • 治疗缓解预测亚组样本量较小(化疗24例,ARTA 20例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aimed to test whether the prognostic value of 18 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) in metastatic castration-resistant prostate cancer (mCRPC) extends to the estimation of systemic treatment response duration. METHODS: mCRPC patients submitted to FDG-PET/CT in four Italian centers from 2005 to 2020 were retrospectively enrolled. Clinical and biochemical data at the time of imaging were collected, and SUV max of the hottest lesion, total metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were calculated. The correlation between PET- and biochemical-derived parameters with Overall Survival (OS) was analysed. The prediction of treatment response duration was assessed in the subgroup submitted to FDG-PET/CT in the six months preceding Chemotherapy (namely Docetaxel or Cabazitaxel, 24 patients) or Androgen-Receptor Targeted Agents (ARTA, namely Abiraterone or Enzalutamide, 20 patients) administration. RESULTS: We enrolled 114 mCRPC patients followed-up for a median interval lasting 15 months. While at univariate analysis, prostate-specific antigen (PSA), Alkaline Phosphatase (ALP), MTV, and TLG were associated with OS, at the multivariate Cox regression analysis, the sole MTV could independently predict OS (p < 0.0001). In the subgroup submitted to FDG-PET/CT before the systemic treatment initiation, PSA and TLG could also predict treatment response duration independently (p < 0.05). Of note, while PSA could not indicate the best treatment choice, lower TLG was associated with higher success rates for ARTA but had no impact on chemotherapy efficacy. CONCLUSIONS: FDG-PET/CT's prognostic value extends to predicting treatment response duration in mCRPC, thus potentially guiding the systemic treatment selection.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Bauckneht M, Bertagna F, Donegani MI, et al. The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients. Prostate Cancer Prostatic Dis. 2021. PMID: 34012060. doi:10.1038/s41391-021-00391-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。